Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Kaplan-Meier method

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44343   clinical trials with a EudraCT protocol, of which   7372   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    187 result(s) found for: Kaplan-Meier method. Displaying page 3 of 10.
    « Previous 1  2  3  4  5  6  7  8  9  Next» Last»»
    EudraCT Number: 2016-002244-16 Sponsor Protocol Number: NRG-HN002 Start Date*: 2016-09-12
    Sponsor Name:Irish Clinical Oncology Research Group CLG, trading as Cancer Trials Ireland
    Full Title: A Randomized Phase II Trial for Patients with p16 Positive, Non-Smoking Associated, Locoregionally Advanced Oropharyngeal Cancer
    Medical condition: Locoregionally advanced oropharyngeal cancer
    Disease: Version SOC Term Classification Code Term Level
    19.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10031096 Oropharyngeal cancer PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2005-002126-64 Sponsor Protocol Number: CA184-004 Start Date*: 2006-05-15
    Sponsor Name:Bristol-Myers Squibb International Corporation
    Full Title: An Exploratory Study to Determine Potential Predictive Markers of Response and/or Toxicity in Patients with Unresectable Stage III or IV Malignant Melanoma Randomized and Treated with Ipilimumab (M...
    Medical condition: Melanoma
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NO (Completed) SE (Completed) DK (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2011-001690-62 Sponsor Protocol Number: HE2016 Start Date*: 2014-09-16
    Sponsor Name:University of Birmingham
    Full Title: A randomised phase II clinical trial of conditioning cyclophosphamide and chemoembolisation with or without vaccination with dendritic cells pulsed with HepG2 lysate ex vivo in patients with Hepato...
    Medical condition: Hepatocellular carcinoma
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10049010 Carcinoma hepatocellular LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2004-002054-55 Sponsor Protocol Number: PXD101-301-G Start Date*: 2006-01-12
    Sponsor Name:Topotarget A/S
    Full Title: A phase II Clinical Trial of PXD101 in Patients with Advanced Multiple Myeloma
    Medical condition: Patients in relapse from prior treatment, with histologically and otherwise verified diagnosis of multiple myeloma.
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Completed) GB (Completed)
    Trial results: View results
    EudraCT Number: 2022-000627-20 Sponsor Protocol Number: F8394-201 Start Date*: 2023-02-07
    Sponsor Name:Fore Biotherapeutics
    Full Title: A Phase 2 Master Protocol to assess the efficacy and safety of FORE8394, an inhibitor of BRAF class 1 and class 2 alterations, in participants with cancer harboring BRAF alterations
    Medical condition: Tumors harboring BRAF alterations
    Disease: Version SOC Term Classification Code Term Level
    23.0 10010331 - Congenital, familial and genetic disorders 10075648 BRAF gene mutation PT
    22.0 10022891 - Investigations 10075676 BRAF V600E mutation positive PT
    Population Age: Children, Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Trial now transitioned) ES (Ongoing) SE (Trial now transitioned) DE (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2004-000330-36 Sponsor Protocol Number: TLK286.3020 Start Date*: 2004-09-07
    Sponsor Name:TELIK, INC.
    Full Title: Phase 3 Randomized Study of TLK286 versus Gefitinib (Iressa) as Third-Line Therapy in Locally Advanced or Metastatic Non-Small Cell Lung Cancer
    Medical condition: Treatment of patients with locally advanced or metastatic non-small cell lung cancer after failure of both platinum-based and docetaxel chemotherapies.
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Ongoing) ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2012-002841-39 Sponsor Protocol Number: GINECO-OV-222 Start Date*: 2013-10-07
    Sponsor Name:ARCAGY GINECO
    Full Title: A randomized, open label, phase II trial of bevacizumab plus weekly paclitaxel followed by bevacizumab monotherapy maintenance versus weekly paclitaxel followed by observation in patients with rela...
    Medical condition: Patients with an histologically confirmed diagnosis of ovarian sex-cord stromal tumor in relapse after a platinum-based chemotherapy.
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10033128 Ovarian cancer PT
    Population Age: Adults Gender: Female
    Trial protocol: DE (Completed) BE (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2016-001193-15 Sponsor Protocol Number: FASTERCC-001 Start Date*: 2016-07-06
    Sponsor Name:Department of Oncology, Aarhus University Hospital
    Full Title: Folic acid supplement versus placebo for treating mucositis adverse events in metastatic renal cell carcinoma patients receiving targeted therapy (FASTERCC). A randomized, double-blind, phase II ...
    Medical condition: Mucositis (nasal, oral, pharyngeal, anal, or genital) is often experienced in relation to TKI and mTOR inhibitor treatment of metastatic renal cell carcinoma patients. The present trial will assess...
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004872 10064282 Vaginal mucositis LLT
    20.0 100000004856 10028130 Mucositis oral LLT
    20.0 100000004856 10065721 Anal mucositis LLT
    20.0 100000004867 10028127 Mucositis LLT
    20.0 100000004855 10065881 Pharyngeal mucositis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2018-004458-14 Sponsor Protocol Number: PROvING Start Date*: 2020-11-05
    Sponsor Name:AZIENDA OSPEDALIERO-UNIVERSITARIA PISANA
    Full Title: Phase III clinical trial Oligometastatic and Oligorecurrent PROstate Cancer: enhancing patients’ selection by new ImagiNG biomarkers
    Medical condition: Prostate cancer
    Disease: Version SOC Term Classification Code Term Level
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10036911 Prostate cancer recurrent PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10007453 Carcinoma of the prostate metastatic LLT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10007454 Carcinoma of the prostate recurrent LLT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10036909 Prostate cancer metastatic PT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2015-004195-30 Sponsor Protocol Number: ABX464-004 Start Date*: 2016-05-24
    Sponsor Name:Abivax
    Full Title: A multi-center, randomized, double-blind, placebo-controlled Phase IIa trial to compare the safety of ABX464 given at a fixed dose to placebo in fully controlled HIV infected patients treated with ...
    Medical condition: Human Immunodeficiency Virus (HIV)
    Disease: Version SOC Term Classification Code Term Level
    19.0 100000004862 10020443 Human immunodeficiency virus syndrome LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: BE (Completed) ES (Completed) FR (Completed)
    Trial results: View results
    EudraCT Number: 2011-004109-25 Sponsor Protocol Number: P261-402 Start Date*: 2012-05-03
    Sponsor Name:Upsher-Smith Laboratories, Inc.
    Full Title: An Open-Label Safety Study of USL261 in the Outpatient Treatment of Subjects with Seizure Clusters
    Medical condition: Epilepsy
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029205 - Nervous system disorders 10015052 Epileptic seizure LLT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Prematurely Ended) DE (Prematurely Ended) HU (Prematurely Ended) PL (Prematurely Ended) IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2018-004180-31 Sponsor Protocol Number: 3119003 Start Date*: 2019-04-29
    Sponsor Name:Orion Corporation
    Full Title: Effects of oral Levosimendan (ODM-109) on respiratory function in patients with ALS: open label extension for patients completing study 3119002
    Medical condition: Amyotrophic Lateral Sclerosis (ALS)
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029205 - Nervous system disorders 10002026 Amyotrophic lateral sclerosis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) ES (Prematurely Ended) DE (Prematurely Ended) FI (Prematurely Ended) AT (Prematurely Ended) NL (Prematurely Ended) IE (Prematurely Ended) GB (GB - no longer in EU/EEA) FR (Completed) IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2018-001132-22 Sponsor Protocol Number: BGB-A317-NSCL-001 Start Date*: 2019-05-20
    Sponsor Name:Celgene Corporation
    Full Title: A Phase 3, Randomized, Blinded, Placebo-controlled Study of Tislelizumab (BGB-A317) Plus Chemoradiotherapy Followed by Tislelizumab Monotherapy in Newly Diagnosed, Stage III Subjects with Locally A...
    Medical condition: non-small cell lung cancer (NSCLC)
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10029519 Non-small cell lung cancer stage III PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10025052 Lung cancer non-small cell stage III LLT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10025054 Lung cancer non-small cell stage IIIB LLT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10025053 Lung cancer non-small cell stage IIIA LLT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10025061 Lung cancer stage III LLT
    20.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10080083 Advanced lung cancer LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: PT (Completed) ES (Prematurely Ended) FI (Prematurely Ended) PL (Completed) HU (Completed) GB (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2020-002392-35 Sponsor Protocol Number: KRT-232-113 Start Date*: 2021-02-05
    Sponsor Name:Kartos Therapeutics, Inc.
    Full Title: An Open-Label, Multicenter, Phase 1b/2 Study of the Safety and Efficacy of KRT-232 with TL-895 in Subjects with Relapsed/Refractory Myelofibrosis and of KRT-232 in Janus-associated Kinase Inhibitor...
    Medical condition: Relapsed/Refractory Myelofibrosis and Janus-associated Kinase Inhibitor-Intolerant Myelofibrosis
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10028537 Myelofibrosis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed) HU (Prematurely Ended) PL (Prematurely Ended) DE (Prematurely Ended) AT (Prematurely Ended) BG (Completed) IT (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2011-002142-13 Sponsor Protocol Number: P06241/P202 Start Date*: 2012-05-30
    Sponsor Name:Merck Sharp & Dohme Corp
    Full Title: A 26-Week Randomized, Double-Blinded, Active Controlled Study Comparing the Safety of Mometasone Furoate/Formoterol Fumarate MDI Fixed Dose Combination Versus Mometasone Furoate MDI Monotherapy in ...
    Medical condition: Persistent Asthma
    Disease: Version SOC Term Classification Code Term Level
    18.0 10038738 - Respiratory, thoracic and mediastinal disorders 10003553 Asthma PT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed) EE (Completed) CZ (Completed) LV (Completed) GB (Completed) ES (Completed) DE (Completed) IE (Completed) SK (Completed) PL (Completed) IT (Completed) BG (Completed) Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2018-000819-25 Sponsor Protocol Number: DS102A-05-AH1 Start Date*: 2019-01-31
    Sponsor Name:Afimmune
    Full Title: A Randomised, Double-Blind, Placebo-Controlled, Phase II Study to Assess the Efficacy and Safety of Orally Administered DS102 in Patients with Severe Acute Decompensated Alcoholic Hepatitis.
    Medical condition: Severe Acute Decompensated Alcoholic Hepatitis
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004871 10001624 Alcoholic hepatitis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Prematurely Ended) FR (Prematurely Ended) DE (Prematurely Ended) LV (Prematurely Ended) GB (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2005-002570-30 Sponsor Protocol Number: EFC5505 Start Date*: 2005-12-07
    Sponsor Name:Sanofi-Synthelabo Recherche
    Full Title: A multicenter, randomized double-blind placebo controlled Phase III study of the efficacy of xaliproden in preventing the neurotoxicity of oxaliplatin in first-line treatment of patients with metas...
    Medical condition: Patients with metastatic colorectal cancer treated with oxaliplatin/5-FU/LV; at risk of cumulative peripheral sensory neuropathy (PSN) relative to cumulative dose of oxaliplatin.
    Disease: Version SOC Term Classification Code Term Level
    8 10034620 LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) HU (Completed) ES (Completed) PT (Prematurely Ended) DE (Prematurely Ended) IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2007-001439-74 Sponsor Protocol Number: 20062080 Start Date*: 2007-09-04
    Sponsor Name:Amgen Inc
    Full Title: A Phase 2, Randomized Trial of Chemoradiation with or without Panitumumab in Subjects with Unresected, Locally Advanced Squamous Cell Carcinoma of the Head and Neck
    Medical condition: Advance Squamous Cell Carcinoma of the Head and Neck
    Disease: Version SOC Term Classification Code Term Level
    9.1 10060121 Squamous cell carcinoma of head and neck LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FI (Completed) HU (Completed) DE (Completed) ES (Completed) IT (Completed) GB (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2017-000160-15 Sponsor Protocol Number: MVT-601-3201 Start Date*: 2017-07-25
    Sponsor Name:Myovant Sciences GmbH
    Full Title: HERO: A Multinational Phase 3 Randomized, Open-label, Parallel Group Study to Evaluate the Safety and Efficacy of Relugolix in Men with Advanced Prostate Cancer
    Medical condition: Androgen-sensitive advanced prostate cancer
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10060862 Prostate cancer PT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: NL (Completed) SE (Completed) GB (GB - no longer in EU/EEA) BE (Completed) AT (Completed) SK (Completed) DK (Completed) FI (Completed) ES (Completed) DE (Completed) PL (Completed) FR (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2010-022240-21 Sponsor Protocol Number: ISIS183750-CS4 Start Date*: 2011-04-29
    Sponsor Name:Isis Pharmaceuticals Inc.
    Full Title: A Phase 1b/2 Study of Carboplatin-Paclitaxel, with or without ISIS 183750 (an eIF4E Inhibitor), in Patients with Stage IV Non-Small Cell Lung Cancer
    Medical condition: Stage IV Non-Small Cell Lung Cancer (NSCLC; including patients with pleural effusion who were previously classified as Stage IIIB)
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10029522 Non-small cell lung cancer stage IV PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Prematurely Ended)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    « Previous 1  2  3  4  5  6  7  8  9  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Mon Jun 16 05:28:06 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA